MedTrace Logo

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

NCT05478707 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-04-09

No results posted yet for this study

Summary

The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Conditions

  • Diabetes Mellitus, Type 1
  • Endothelial Dysfunction

Interventions

DRUG

Dulaglutide

GLP1-RA

DRUG

Placebo

Saline placebo

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Kaitlin Love, MD · Associate Professor - Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2028-06-30
Completion
2028-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478707 on ClinicalTrials.gov